Fabrice Barlesi

ScholarGPS® ID: 23223642567172

Affiliation

Aix-Marseille University, Aix-en-Provence and Marseille, France

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

505

Predicted Citations

17,173

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. (journal article) Dziadziuszko, Rafal \| Barlesi, Fabrice \| Kim, Jeong Eun \| Gadgeel, Shirish M. \| Krzakowski, Maciej \| Jeong, Jae Ho \| Daniele, Gennaro \| Chen, David \| Hu, Youyou \| Wilson, Timothy R. \| ... \| Thomas, David Morgan Journal of Clinical Oncology, volume 42, issue 17_suppl, pages LBA2509-LBA2509 (2024). 10.1200/JCO.2024.42.17_suppl.LBA2509 Cite \| Source
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy. (journal article) Marinello, Arianna \| Zrafi, Wael \| Zullo, Lodovica \| Lacroix, Ludovic \| Vasseur, Damien \| Nicotra, Claudio \| Lavaud, Pernelle \| Frelaut, Maxime \| Abdayem, Pamela \| Parisi, Claudia \| ... \| Aldea, Mihaela Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 8535-8535 (2024). 10.1200/JCO.2024.42.16_suppl.8535 Cite \| Source
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK + non-small cell lung cancer (NSCLC): Data from ALINA. (journal article) Nishio, Makoto \| Wu, Yi-Long \| Barlesi, Fabrice \| Ahn, Jin Seok \| Lee, Dae Ho \| Lee, Jong-Seok \| Zhong, Wenzhao \| Horinouchi, Hidehito \| Hochmair, Maximilian \| Tanaka, Hiroshi \| ... \| Solomon, Benjamin J. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 8006-8006 (2024). 10.1200/JCO.2024.42.16_suppl.8006 Cite \| Source
Ipatasertib in patients with AKT1/2/3 mutation-positive ( AKT mut) tumors: TAPISTRY study. (journal article) Thomas, David Morgan \| Daniele, Gennaro \| Kim, Jeong Eun \| Gadgeel, Shirish M. \| Ahn, Eugene R. \| Paz-Ares, Luis G. \| Prenen, Hans \| Chen, David \| Fang, Junhan \| Wilson, Timothy R. \| ... \| Barlesi, Fabrice Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 3092-3092 (2024). 10.1200/JCO.2024.42.16_suppl.3092 Cite \| Source
CD8 radiomics signature to assess inter-lesion spatial heterogeneity and cold liver lesions in advanced non-small cell lung cancers treated with durvalumab. (journal article) Sun, Roger \| Emeriau, Yanis \| Achkar, Samir \| Mitrea, Diana \| Laville, Adrien \| Deny, Nicolas \| Bockel, Sophie \| Chaffai, Ines \| Mrissa, Linda \| Cifliku, Vjona \| ... \| Deutsch, Eric Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 2511-2511 (2024). 10.1200/JCO.2024.42.16_suppl.2511 Cite \| Source
Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202). (journal article) Barlesi, Fabrice \| Felip, Enriqueta \| Popat, Sanjay \| Solomon, Benjamin J. \| Wolf, Juergen \| Li, Bob T. \| Wu, Yi-Long \| Kerr, Keith \| Akamatsu, Hiroaki \| Camidge, David Ross \| ... \| Borghaei, Hossein Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS8653-TPS8653 (2024). 10.1200/JCO.2024.42.16_suppl.TPS8653 Cite \| Source
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). (journal article) Aggarwal, Charu \| Martinez-Marti, Alex \| Majem, Margarita \| Barlesi, Fabrice \| Carcereny, Enric \| Chu, Quincy S. \| Monnet, Isabelle \| Sanchez, Alfredo \| Dakhil, Shaker R. \| Camidge, David Ross \| ... \| Herbst, Roy S. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 8046-8046 (2024). 10.1200/JCO.2024.42.16_suppl.8046 Cited by (1) \| Cite \| Source
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations (journal article) Rached, Layal \| Laparra, Ariane \| Sakkal, Madona \| Danlos, François-Xavier \| Barlesi, Fabrice \| Carbonnel, Franck \| De Martin, Eleonora \| Ducreux, Michel \| Even, Caroline \| Le Pavec, Jerome \| ... \| Champiat, Stéphane Cancer Treatment Reviews, volume 127 (2024). 10.1016/j.ctrv.2024.102751 Cited by (2) \| Cite \| Source
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort (journal article) Remon, J. \| Auclin, E. \| Zubiri, L. \| Schneider, S. \| Rodriguez-Abreu, D. \| Minatta, N. \| Gautschi, O. \| Aboubakar, F. \| Muñoz-Couselo, E. \| Pierret, T. \| ... \| Besse, B.M.D. ESMO Open, volume 9, issue 5, pages 103004- (2024). 10.1016/j.esmoop.2024.103004 Cite \| Source
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial (journal article) Baptiste Oudart, Jean \| Garinet, Simon \| Leger, Caroline \| Barlesi, Fabrice \| Mazières, Julien \| Jeannin, Gaelle \| Audigier-Valette, Clarisse \| Morot-Sibilot, Denis \| Langlais, Alexandra \| Amour, Elodie \| ... \| Wislez, Marie Lung Cancer, volume 190 (2024). 10.1016/j.lungcan.2024.107508 Cite \| Source
Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model (journal article) Sicard, Guillaume \| Protzenko, Dorian \| Giacometti, Sarah \| Barlési, Fabrice \| Ciccolini, Joseph \| Fanciullino, Raphaelle Cancer Drug Resistance (2024). 10.20517/cdr.2023.146 Cite \| Source
242P Prognostic role of tumor microenvironment features in advanced non-small cell lung cancer molecular subtypes: A multicentric, retrospective study (journal article) Zullo, L. \| Marinello, A. \| Ghigna, M.R. \| De Maglio, G. \| Citarella, F. \| Pagliaro, A. \| Gazzah, A. \| Lavaud, P. \| Abdayem, P. \| Frelaut, M. \| ... \| Aldea, M. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.102892 Cite \| Source
193O Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial (journal article) Walls, G. \| Mistry, H. \| Barlesi, F. \| Bezjak, A. \| Le Pechoux, C. \| O'Brien, M.E.R. \| van Meerbeeck, J.P. \| Blackhall, F. \| Faivre-Finn, C. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.102766 Cite \| Source
103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202) (journal article) Barlesi, F. \| Felip, E. \| Popat, S. \| Solomon, B. \| Wolf, J. \| Li, B.T. \| Wu, Y-L. \| Kerr, K.M. \| Akamatsu, H. \| Camidge, D.R. \| ... \| Borghaei, H. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.102682 Cited by (1) \| Cite \| Source
Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial (journal article) Walls, Gerard M. \| Mistry, Hitesh \| Barlesi, Fabrice \| Bezjak, Andrea \| Pechoux, Cecile Le \| O'Brien, Mary \| Van Meerbeeck, Jan P. \| Blackhall, Fiona \| Faivre-Finn, Corinne International Journal of Radiation OncologyBiologyPhysics (2024). 10.1016/j.ijrobp.2024.02.063 Cite \| Source
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan (journal article) Leal, Ticiana A. \| Dasgupta, Anandaroop \| Latremouille-Viau, Dominick \| Rossi, Carmine \| Rai, Pragya \| Barlesi, Fabrice \| Liu, Stephen V. JCO Global Oncology (2024). 10.1200/GO.23.00483 Cite \| Source
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors (journal article) Khushalani, Nikhil I \| Ott, Patrick A \| Ferris, Robert L \| Cascone, Tina \| Schadendorf, Dirk \| Le, Dung T \| Sharma, Manish R \| Barlesi, Fabrice \| Sharfman, William \| Luke, Jason J \| ... \| Segal, Neil H Journal for ImmunoTherapy of Cancer, volume 12, issue 3, pages e007364- (2024). 10.1136/jitc-2023-007364 Cite \| Source
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer (journal article) Bessede, Alban \| Peyraud, Florent \| Besse, Benjamin \| Cousin, Sophie \| Cabart, Mathilde \| Chomy, François \| Rey, Christophe \| Lara, Oren \| Odin, Ophélie \| Nafia, Imane \| ... \| Italiano, Antoine Clinical Cancer Research, volume 30, issue 4, pages 779-785 (2024). 10.1158/1078-0432.CCR-23-2566 Cite \| Source
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial (journal article) Reck, Martin \| Barlesi, Fabrice \| Yang, James Chih-Hsin \| Westeel, Virginie \| Felip, Enriqueta \| Özgüroğlu, Mustafa \| Dols, Manuel Cobo \| Sullivan, Richard \| Kowalski, Dariusz M. \| Andric, Zoran \| ... \| Park, Keunchil Journal of Thoracic Oncology, volume 19, issue 2, pages 297-313 (2024). 10.1016/j.jtho.2023.09.1445 Cited by (1) \| Cite \| Source
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial (journal article) Garon, Edward B. \| Lu, Shun \| Goto, Yasushi \| De Marchi, Pedro \| Paz-Ares, Luis \| Spigel, David R. \| Thomas, Michael \| Yang, James Chih-Hsin \| Ardizzoni, Andrea \| Barlesi, Fabrice \| ... \| Cho, Byoung Chul Journal of Clinical Oncology, volume 42, issue 2, pages 180-191 (2024). 10.1200/JCO.23.00910 Cited by (6) \| Cite \| Source